Dr. Martens (LON:DOCS) Issues Quarterly Earnings Results

Dr. Martens (LON:DOCS) posted its earnings results on Thursday. The company reported GBX (1) EPS for the quarter, Digital Look Earnings reports. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. The business had revenue of £290.40 million during the quarter.

Here are the key takeaways from Dr. Martens’ conference call:

• Revenue fell 9.2% year over year to £292.4 million, and adjusted EBIT swung to a £2.2 million loss from a £3.1 million profit. The decline was concentrated in Europe and DTC, with boots sales down 20% amid unusually hot weather and ongoing pressure on core styles.
• Margin and cost discipline cushioned the sales decline: gross margin rose 80 basis points on a comparable basis to 65.4%, while operating costs benefited from prior cost actions. Management said margin should remain resilient, though some first-half benefits may ease in the second half.
• Debt remained broadly flat year over year at £158.9 million, and covenant net debt to EBITDA was 2.2 times versus a 3.0-times limit. Cash generation was seasonally negative by £66.2 million as the company built working capital ahead of peak trading.
• The company reported encouraging early responses to its With Bouncing Soles campaign, upgraded Brand Centres, and new Spring/Summer sandals range. Management cautioned that the campaign and store results are still early, and the new e-commerce platform has required time to bed in.
• Second-half performance is pivotal: management expects boots to remain a headwind for the rest of FY 2027, with core boot styles still under pressure, and said the business is focused on the key trading weeks ahead. Its full-price mix priorities in the U.K. and DACH are weighted to the second half.

Dr. Martens Trading Down 16.8%

Dr. Martens stock traded down GBX 10.90 during trading on Thursday, hitting GBX 54.10. The company had a trading volume of 12,470,877 shares, compared to its average volume of 6,074,340. The stock has a market cap of £517.88 million, a price-to-earnings ratio of 22.54, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.85. Dr. Martens has a 1-year low of GBX 52.10 and a 1-year high of GBX 90. The company’s 50 day simple moving average is GBX 67.13 and its 200-day simple moving average is GBX 69.53.

Insider Buying and Selling

In other Dr. Martens news, insider Ije Nwokori sold 209,160 shares of the company’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of GBX 69, for a total transaction of £144,320.40. Insiders acquired 927 shares of company stock worth $59,965 in the last 90 days. 2.97% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank reiterated a “buy” rating and set a GBX 110 price target on shares of Dr. Martens in a report on Friday, October 9th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Dr. Martens has a consensus rating of “Moderate Buy” and a consensus target price of GBX 105.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.